Boston Scientific Soars 3.49% on 23% Revenue Surge

On July 23, 2025, Boston Scientific's stock rose by 3.49% in pre-market trading, reflecting strong investor confidence in the company's recent financial performance and future prospects.

Boston Scientific reported impressive second-quarter results, with revenue increasing by 23% year-over-year to $50.6 billion, surpassing analyst expectations of $48.9 billion. The company's cardiovascular division saw a significant 29% increase in sales, reaching $26.5 billion. Net income for the quarter was $7.97 billion, a substantial 146% increase from the previous year. Adjusted earnings per share (EPS) stood at $0.75, exceeding analyst forecasts of $0.73.

Looking ahead, Boston Scientific reaffirmed its full-year sales growth target of 18% to 19% based on 2024's $167.5 billion in sales. The company also raised its adjusted EPS guidance for 2025 to a range of $2.95 to $2.99, up from the previous range of $2.87 to $2.94. This optimistic outlook is supported by the company's strong performance in the first half of the year, with cumulative revenue of $97.24 billion, a 21.9% increase from the previous year, and net income of $14.67 billion, an 80% increase year-over-year.